ESPE2016 Poster Presentations Diabetes P2 (73 abstracts)
Which Group of Children Achieved the Best Results During Insulin Pump Therapy – Long-term Outcome in Children with Type 1 Diabetes?
Iwona Ben-Skowronek , Robert Piekarski , Beata Wysocka , Anna Bury , Bozena Banecka , Aleksandra Krzewska , Joanna Sieniawska , Magdalena Kabat , Katarzyna Rebowicz , Wiktoria Osiak & Leszek Szewczyk
Department of Pediatric Endocrinology and Diabetology Medical University of Lublin, Lublin, Poland
Background: CSII has some potential advantages and disadvantages for young children. For many young patients, it is easier and more convenient to take multiple daily doses of insulin with CSII than with a syringe or insulin pen.
Objective and hypotheses: The growing popularity of type 1 diabetes (DM1) treatment based on continuous subcutaneous insulin infusion (CSII) raises a question of the group of patients that benefit most from the treatment.
Method: Clinical observation was carried out in 285 1-18-year-old patients diagnosed with DM1 treated with CSII. Every 3 months, HbA1c was determined by an agglutination inhibition immunoassay. The patients were followed for 6–10 years.
Results: The greatest benefits from the treatment with CSII using an insulin pump were noted in type 1 diabetes children aged 1–5: the mean HbA1c decreased in these patients from 7.98% to 6.75% (P<0.01) over 6 years. Slightly lesser outcomes were noted in the group of 6–10-year olds: the mean HbA1c value increased slightly from 7.6% before the CSII to 7.89% after 6 years of treatment (P>0.01). Somewhat worse outcomes were reported in the group of 11–15-year-old children: HbA1c increased from 8.05% to 8.72% (P>0.01). The lowest outcomes were found in the group of the 16–19-year-old patients, as HbA1c rose from 7.8% to 8.82% (P<0.01) over 6 years. The children receiving the CSII treatment as early as in the first year of treatment exhibited better diabetes control (HbA1c 8.1% declined after 6 years to do 7.1%, P<0.01) than patients who received CSII at an older age (HbA1c increased from 7.92% to 8.2%, P<0.01).
Conclusion: The CSII on offers the greatest benefits for patients aged 1–5 and those with the treatment commenced in the first year after diagnosis of type 1 diabetes. The best results this group of children achieved 6 or more years after start of the pump therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more